Estrogens, homocysteine, vasodilatation and menopause: Basic mechanisms, interactions and clinical implications

Gynecological Endocrinology

Volumn 17, Issue 4, 2003, Pages 339-354

  Smolders, R G V ^b   Van Der Mooren, M J ^a   Sipkema, P ^a   Kenemans, P ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Dept of Obstetrics and Gynecology ^*

Author keywords

Estrogen; Homocysteine; Interaction; Mechanisms; Vasodilatation

Indexed keywords

ANTIOXIDANT; CALCIUM ION; CONJUGATED ESTROGEN; CYANOCOBALAMIN; DYDROGESTERONE; ESTRADIOL; ESTROGEN RECEPTOR; GESTAGEN; HOMOCYSTEINE; MEDROXYPROGESTERONE ACETATE; NITRIC OXIDE SYNTHASE; ORAL CONTRACEPTIVE AGENT; PLACEBO; POTASSIUM; POTASSIUM CHANNEL; RALOXIFENE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTERY WALL; CALCIUM TRANSPORT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DEMETHYLATION; DNA METHYLATION; DNA TRANSCRIPTION; ENDOTHELIUM CELL; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; MENOPAUSAL SYNDROME; METABOLISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; VASODILATATION;

EID: 0042833283     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.17.4.339.354     Document Type: Review

References (166)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76
2. Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet 1999;353:89-92
3. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993;329:247-56
4. Van der Schouw YT, van der Graaf Y, Teyerberg EW, et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714-18
5. Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002;53:550-7
6. Van Baal WM, Kooistra T, Stehouwer CDA. Cardiovascular disease risk and hormone replacement therapy (hrt): a review based on randomised, controlled studies in postmenopausal women. Curr Med Chem 2000;7:499-517
7. Roeters van Lennep JE, Westerveld HT, Erkelens DW, et al. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 2002;53:538-49
8. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605-13
9. Folkow B. Myogenic mechanisms in the control of systemic resistance. Introduction and historical background. J Hypertens Suppl 1989;7:S1-4
10. Davis MJ. Microvascular control of capillary pressure during increases in local arterial and venous pressure. Am J Physiol 1988;254:H772-84
11. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev 1990;70:921-61
12. Faraci FM, Heistad DD. Regulation of large cerebral arteries and cerebral microvascular pressure. Circ Res 1990;66:8-17
13. Iida N. Different flow regulation mechanisms between celiac and mesenteric vascular beds in conscious rats. Hypertension 1995;25:260-5
14. Welsh DG, Morielli AD, Nelson MT, et al. Transient receptor potential channels regulate myogenic tone of resistance arteries. Circ Res 2002;90:248-50
15. Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9
16. Ignarro LJ. Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension 1990;16:477-83
17. Somlyo AV, Somlyo AP. Electromechanical and pharmacological coupling in vascular smooth muscle. J Pharmacol Exp Ther 1968;159:129-45
18. Somlyo AP, Bond M, Somlyo AV. Calcium content of mitochondria and endoplasmic reticulum in liver frozen rapidly in vivo. Nature 1985;314:622-5
19. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature 1994;372:231-6
20. Walsh MP, Kargacin GJ, Kendrick-Jones J, et al. Intracellular mechanisms involved in the regulation of vascular smooth muscle tone. Can J Physiol Pharmacol 1995;73:565-73
21. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990;30:535-60
22. Ignarro LJ, Cirino G, Casini A, et al. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999;34:879-86
23. Davis MJ, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999;79:387-423
24. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26
25. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide 2001;5:88-97
26. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11
27. Mendelsohn ME. Mechanisms of estrogen action in the cardiovascular system. J Steroid Biochem Mol Biol 2000;74:337-43
28. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomised monkeys: lack of an effect of added progesterone. Atherosclerosis 1990;10:1051-7
29. Wagner JD, St Clair RW, Schwenke DC, et al. Regional differences in arterial low density, lipoprotein metabolism in surgically postmenopausal cynomolgus monkeys. Effects of estrogen and progesterone replacement therapy. Arterioscler Thromb 1992;12:717-26
30. Williams JK, Shively CA, Clarkson TB. Determinants of coronary artery reactivity in premenopausal female cynomolgus monkeys with diet-induced atherosclerosis. Circulation 1994;90:983-7
31. Williams JK, Honore EK, Washburn SA, et al. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994;24:1757-61
32. Register TC, Adams MR, Golden DL, et al. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vast Biol 1998;18:1164-71
33. Williams JK, Adams MR, Herrington DM, et al. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992;20:452-7
34. Collins P, Rosano GM, Sarrel PM, et al. 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30
35. Gilligan DM, Badar DM, Panza JA, et al. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994;90:786-91
36. Gilligan DM, Quyyumi AA, Cannon RO III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994;89:2545-51
37. Reis SE, Gloth ST, Blumenthal KS, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60
38. Volterrani M, Rosano G, Coats A, et al. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med 1995;99:119-22
39. Guetta V, Quyyumi AA, Prasad A, et al. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997;96:2795-801
40. Al Khalili F, Eriksson M, Landgren BM, et al. Effect of conjugated estrogen on peripheral flow-mediated vasodilation in postmenopausal women. Am J Cardiol 1998;82:215-18
41. Roque M, Heras M, Roig E, et al. Short-term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms. J Am Coll Cardiol 1998;31:139-43
42. Giltay EJ, Lambert J, Gooren LJ, et al. Sex steroids, insulin, and arterial stiffness in women and men. Hypertension 1999;34:590-7
43. Pirhonen JP, Vuento MH, Makinen JI, et al. Long-term effects of hormone replacement therapy on the uterus and on uterine circulation. Am J Obstet Gynecol 1993;168:620-30
44. Zalud I, Conway C, Schulman H, et al. Endometrial and myometrial thickness and uterine blood flow in postmenopausal women: the influence of hormonal replacement therapy and age [see comments]. J Ultrasound Med 1993;12:737-41
45. Belfort MA, Saade GR, Snabes M, et al. Hormonal status affects the reactivity of the cerebral vasculature. Am J Obstet Gynecol 1995;172:1273-8
46. Bonilla-Musoles F, Ballester MJ, Marti MC, et al. Transvaginal color Doppler assessment of endometrial status in normal postmenopausal women: the effect of hormone replacement therapy. J Ultrasound Med 1995;14:503-7
47. Penotti M, Farina M, Castiglioni E, et al. Alteration in the pulsatility index values of the internal carotid and middle cerebral arteries after suspension of postmenopausal hormone replacement therapy: a randomized crossover study. Am J Obstet Gynecol 1996;175:606-11
48. Hata K, Hata T. Effects of oophorectomy and hormone replacement therapy on ophthalmic artery blood flow velocity waveforms. J Ultrasound Med 1997;16:737-41
49. Jackson S, Vyas S. A double-blind, placebo controlled study of postmenopausal oestrogen replacement therapy and carotid artery pulsatility index. Br J Obstet Gynaecol 1998;105:408-12
50. Van Baal WM, Kenemans P, Stehouwer CDA, et al. Sequentially combined hormone replacement therapy reduces impedance to flow within the uterine and central retinal arteries in healthy postmenopausal women. Am J Obstet Gynecol 1999;181:1365-73
51. Post MS, van der Mooren MJ, van Baal WM, et al. Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study. Am J Obstet Gynecol 2001;185:557-62
52. Jiang CW, Sarrel PM, Lindsay DC, et al. Endothelium-independent relaxation of rabbit coronary artery by 17 beta-oestradiol in vitro. Br J Pharmacol 1991;104:1033-7
53. Jiang C, Sarrel PM, Poole-Wilson PA, et al. Acute effect of 17 beta-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol 1992;263:H271-5
54. Kitazawa T, Hamada E, Kitazawa K, et al. Non-genomic mechanism of 17 beta-oestradiol-induced inhibition of contraction in mammalian vascular smooth muscle. J Physiol 1997;499:497-511
55. Teoh H, Leung SW, Man RY. Short-term exposure to physiological levels of 17 beta-estradiol enhances endothelium-independent relaxation in porcine coronary artery. Cardiovasc Res 1999;42:224-31
56. Vedernikov YP, Liao QP, Jain V, et al. Effect of chronic treatment with 17beta-estradiol and progesterone on endothelium-dependent and endothelium-independent relaxation in isolated aortic rings from ovariectomized rats. Am J Obstet Gynecol 1997;176:603-8
57. 2+ mobilization. Circ Res 1997;81:885-92
58. MacRitchie AN, Jun SS, Chen Z, et al. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal puhnonary artery endothelium. Circ Res 1997;81:335-62
59. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, et al. Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol 1997;273:L119-26
60. Stefano GB, Prevot V, Beauvillain JC, et al. Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia. Circulation 2000;101:1594-7
61. Huang A, Sun D, Kaley G, et al. Estrogen preserves regulation of shear stress by nitric oxide in arterioles of female hypertensive rats. Hypertension 1998;31:309-14
62. Huang A, Sun D, Koller A, et al. Gender difference in flow-induced dilation and regulation of shear stress: role of estrogen and nitric oxide. Am J Physiol 1998;275:R1571-7
63. Huang A, Sun D, Kaley G, et al. Estrogen maintains nitric oxide synthesis in arterioles of female hypertensive rats. Hypertension 1997;29:1351-6
64. Huang A, Sun D, Koller A, et al. Gender difference in myogenic tone of rat arterioles is due to estrogen-induced, enhanced release of NO. Am J Physiol 1997;272:H1804-9
65. Smolders RGV, van der Mooren MJ, Kenemans P, et al. 17-beta estradiol induces a rapid, endothelium-dependent, sex-specific, vasodilatation in spontaneous constricted rat arterioles. Am J Obstet Gynecol 2002;187:375-81
66. 2+ release induced by thromboxane A2 in porcine coronary artery. Circulation 1995;91:2619-26
67. Dantas AP, Tostes RC, Fortes ZB, et al. In vivo evidence for antioxidant potential of estrogen in microvessels of female spontaneously hypertensive rats. Hypertension 2002;39:405-11
68. 2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol 1992;106:739-45
69. Collins P, Beale CM, Rosano GM. Oestrogen as a calcium channel blocker. Eur Heart J 1996;17(Suppl D):27-31
70. White RE, Darkow DJ, Lang JL. Estrogen relaxes coronary arteries bv opening BKCa channels through a cGMP-dependent mechanism. Circ Res 1995;77:936-42
71. Wellman GC, Bonev AD, Nelson MT, et al. Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca(2+)-dependent K+ channels. Circ Res 1996;79:1024-30
72. White RE, Han G, Maunz M, et al. Endothelium-independent effect of estrogen on Ca(2+)-activated K(+) channels in human coronary artery smooth muscle cells. Cardiovasc Res 2002;53:650-61
73. Razandi M, Pedram A, Greene GL, et al. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol 1999;13:307-19
74. Russell KS, Haynes MP, Sinha D, et al. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci USA 2000;97:5930-5
75. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the P13-kinase-akt pathway in human endothelial cells. Circ Res 2000;87:677-82
76. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538-41
77. Chambliss KL, Yuhanna IS, Mineo C, et al. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res 2000;87:E44-52
78. Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999;103:401-6
79. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 2002;105:1368-73
80. Weiner CP, Lizasoain I, Baylis SA, et al. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994;91:5212-16
81. Sudhir K, Jennings GL, Funder JW, et al. Estrogen enhances basal nitric oxide release in the forearm vasculature in perimenopausal women. Hypertension 1996;28:330-4
82. Rubanyi GM, Freay AD, Kauser K, et al. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption. J Clin Invest 1997;99:2429-37
83. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 1998;157(Suppl 2): S40-4
84. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 1996;143:845-59
85. Siri PW, Verhoef P, Kok FJ. Vitamins B6, B12, and folate: association with plasma total homocysteine and risk of coronary atherosclerosis. J Am Coll Nutr 1998;17:435-41
86. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995;10:111-13
87. Kang SS, Passen EL, Ruggie N, et al. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993;88:1463-9
88. Fohr IP, Prinz-Langenohl R, Bronstrup A, et al. 5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. Am J Clin Nutr 2002;75:275-82
89. Carey MC, Donovan DE, FitzGerald O, et al. Homocystinuria. I. A clinical and pathological study of nine subjects in six families. Am J Med 1968;45:7-25
90. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28
91. Finkelstein JD, Kyle WE, Harris BJ. Methionine metabolism in mammals: regulatory effects of S-adenosylhomocysteine. Arch Biochem Biophys 1974;165:774-9
92. Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost 2000;26:219-25
93. Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012-17
94. Tyagi SC, Smiley LM, Mujumdar VS. Homocyst(e)ine impairs endocardial endothelial function. Can J Physiol Pharmacol 1999;77:950-7
95. Ungvari Z, Pacher P, Rischak K, et al. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 1999;19:1899-904
96. Ungvari Z, Koller A. Homocysteine reduces smooth muscle [Ca2+]i and constrictor responses of isolated arterioles. J Cardiovasc Pharmacol 2001;37:705-12
97. Van Guldener C, Stehouwer CDA. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost 2000;26:281-9
98. Raghuveer G, Sinkey CA, Chenard C, et al. Effect of vitamin E on resistance vessel endothelial dysfunction induced by methionine. Am J Cardiol 2001;88:285-90
99. Heinecke JW, Rosen H, Suzuki LA, et al. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262:10098-103
100. Elliott SJ, Koliwad SK. Redox control of ion channel activity in vascular endothelial cells by glutathione. Microcirculation 1997;4:341-7
101. Weiss N, Heydrick S, Zhang YY, et al. Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. Arterioscler Thromb Vasc Biol 2002;22:34-41
102. Weiss N, Zhang YY, Heydrick S, et al. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl Acad Sci USA 2001;98:12503-8
103. Tawakol A, Omland T, Gerhard M, et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-21
104. Chambers JC, McGregor A, Jean-Marie J, et al. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998;351:36-7
105. Bellamy MF, McDowell IF, Ramsey MW, et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998;98:1848-52
106. Boger RH, Bode-Boger SM, Sydow K, et al. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:1557-64
107. Boger RH, Lentz SR, Bode-Boger SM, et al. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 2001;100:161-7
108. Stuhlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569-75
109. Boushey CJ, Beresford SA, Omenn GS. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995;274:1049-57
110. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992;268:877-81
111. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J Am Med Assoc 1997;277:1775-81
112. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6
113. Refsum H, Ueland PM, Nygard O, et al. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62
114. Steegers-Theunissen RP, Boers GH, Trijbels FJ, et al. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism 1994;43:1475-80
115. Steegers-Theunissen RP, Boers GH, Blom HJ, et al. Hyperhomocysteinemia and recurrent spontaneous abortion or abruptio placentae. Lancet 1992;339:1122-3
116. Nelen WL, Blom HJ, Steegers EA, et al. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril 2000;74:1196-9
117. Goddijn-Wessel TA, Wouters MG, van de Molen EF, et al. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol 1996;66:23-9
118. De Vries JI, Dekker GA, Huijgens PC, et al. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997;104:1248-54
119. Dimitrova KR, DeGroot K, Myers AK, et al. Estrogen and homocysteine. Cardiovasc Res 2002;53:577-88
120. Stehouwer CDA. Heterogeneity of the association between plasma homocysteine and atherothrombotic disease: insights from studies of vascular structure and function. Clin Chem Lab Med 2001;39:705-9
121. Blundell G, Jones BG, Nose FA, et al. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996;122:163-72
122. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:2074-81
123. Tyagi SC. Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol 2001;274:C396-405
124. Hultberg B, Andersson A, Isaksson A. Hypomethylation as a cause of homocysteine-induced cell damage in human cell lines. Toxicology 2000;147:69-75
125. Harrington EO, Smeglin A, Newton J, et al. Protein tyrosine phosphatase-dependent proteolysis of focal adhesion complexes in endothelial cell apoptosis. Am J Physiol 2001;280:L342-53
126. Mijatovic V, van der Mooren MJ. Homocysteine in postmenopausal women and the importance of hormone replacement therapy. Clin Chem Lab Med 2001;39:764-7
127. Giltay EJ, Hoogeveen EK, Elbers JH, et al. Effects of sex steroids on plasma total homocysteine levels - a study in transsexual males and females. J Clin Endocrinol Metab 1998;83:550-3
128. De Bree A, Verschuren WM, Blom HJ, et al. Association between B vitamin intake and plasma homocysteine concentration in the general Dutch population aged 20-65 y. Am J Clin Nutr 2001;73:1027-33
129. Carmel R, Howard JM, Green R, et al. Hormone replacement therapy and cobalamin status in elderly women. Am J Clin Nutr 1996;64:856-9
130. Steegers-Theunissen RP, Boers GH, Steegers EA, et al. Effects of sub-50 oral contraceptives on homocysteine metabolism: a preliminary study. Contraception 1992;45:129-39
131. O'Connor DL, Green T, Picciano MF. Maternal folate status and lactation. J Mammary Gland Biol Neoplasia 1997;2:279-89
132. Steegers-Theunissen RP, Wathen NC, Eskes TK, et al. Maternal and fetal levels of methionine and homocysteine in early human pregnancy. Br J Obstet Gynaecol 1997;104:20-4
133. Olszewski AJ, McCully KS. Homocysteine content of lipoproteins in hypercholesterolaemia. Atherosclerosis 1991;88:61-8
134. Windler EE, Kovanen PT, Chao YS, et al. The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem 1980;255:10464-71
135. Brown CA, McKinney KQ, Young KB, et al. The C677T methylenetetrahydrofolate reductase polymorphism influences the homocysteine-lowering effect of hormone replacement therapy. Mol Genet Metab 1999;67:43-8
136. Blom HJ, van der Mooren MJ. Hyperhomocysteinemia: a risk factor for cardiovascular disease - influence of sex hormones on homocysteine metabolism. Gynecol Endocrinol 1996;10:75-9
137. Boers GH, Smals AG, Trijbels FJ, et al. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983;72:1971-6
138. Wouters MG, Moorrees MT, van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995;25:801-5
139. Hak AE, Polderman KH, Westendorp IC, et al. Increased plasma homocysteine after menopause. Atherosclerosis 2000;149:163-8
140. Van der Mooren MJ, Wouters MG, Blom HJ, et al. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994;24:733-6
141. Van der Mooren MJ, Demacker PN, Blom HJ, et al. The effect of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women. Fertil Steril 1997;67:67-73
142. Mijatovic V, Kenemans P, Netelenbos C, et al. Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 1998;69:876-82
143. Mijatovic V, Kenemans P, Jakobs C, et al. A randomized controlled study of the effects of 17beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol 1998;91:432-6
144. Mijatovic V, Netelenbos C, van der Mooren MJ, et al. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril 1998;70:1085-9
145. Van Baal WM, Smolders RGV, van der Mooren MJ, et al. Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol 1999;94:485-91
146. Barnabei VM, Phillips TM Hsia J. Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Womens Health Gend Based Med 1999;8:1167-72
147. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women; a randomized, controlled trial. J Clin Endocrinol Metab 2000;85:214-18
148. Ventura P, Cagnacci A, Malmusi S, et al. Continuous combined hormone replacement therapy with oral 17 beta-estradiol and norethisterone acetate improves homocysteine metabolism in postmenopausal women. Menopause 2001;8:252-8
149. Hak AE, Bak AA, Lindemans J, et al. The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled trial. Atherosclerosis 2001;158:437-43
150. Somekawa Y, Kobayashi K, Tomura S, et al. Effects of hormone replacement therapy and methylenetetrahydrofolate reductase polymorphism on plasma folate and homocysteine levels in postmenopausal Japanese women. Fertil Steril 2002;77:481-6
151. Yildirir A, Aybar F, Tokgozoglu L, et al. Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels. Gynecol Obstet Invest 2002;53:54-8
152. Smolders RGV, Vogelvang TE, Mijatovic V, et al. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas 2002;41:105-14
153. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9
154. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61
155. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72
156. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. J Am Med Assoc 1998;279:359-64
157. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyperhomocyst(e)inaemia. Lancet 1998;351:263
158. Vermeulen EG, Stehouwer CDA, Twisk JW, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of sub-clinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000;355:517-22
159. Thakur MK, Kanungo MS. Methylation of chromosomal proteins and DNA of rat brain and its modulation by estradiol and calcium during aging. Exp Gerontol 1981;16:331-6
160. Wilks AF, Cozens PJ, Mattaj IW, et al. Estrogen induces a demethylation at the 5′ end region of the chicken vitellogenin gene. Proc Natl Acad Sci USA 1982;79:4252-5
161. Wilks A, Seldran M, Jost JP. An estrogen-dependent demethylation at the 5′ end of the chicken vitellogenin gene is independent of DNA synthesis. Nucleic Acids Res 1984;12:1163-77
162. Lu LJ, Liehr JG, Sirbasku DA, et al. Hypomethylation of DNA in estrogen-induced and -dependent hamster kidney tumors. Carcinogenesis 1988;9:925-9
163. Thakur MK, Kaur J. Methylation of DNA and its modulation by estrogen in the uterus of aging rats. Cell Mol Biol 1992;38:525-32
164. Li S, Washburn KA, Moore R, et al. Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. Cancer Res 1997;57:4356-9
165. Lyons AS, Petrucelli RJ. Hippocrates. In Medicine: an Illustrated History. New York: Abradale Press, 1990:207-19
166. Evio S, Tiitinen A, Turpeinen U, et al. Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertil Steril 2000;74:1080-3